- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03756649
Mayo Clinic IBD Biobank
February 12, 2026 updated by: Konstantinos N. Lazaridis, M.D., Mayo Clinic
Researchers are collecting and storing blood, stool, and urine samples and medical information to better understand Inflammatory Bowel Disease (IBD) to improve disease outcome.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
Subjects will be sent a letter detailing the proposed biobank and soliciting enrollment.
Following the informed consent process, subjects will provide a blood sample (50 ml), urine sample (50 ml), and stool.
The blood and urine samples will either be collected at the one of the Mayo Clinic outpatient laboratories or by a mail-out kit.
Subjects will be asked to complete a questionnaire and 24-hour food recall questionnaire (completed online).
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Probability Sample
Study Population
Patients diagnosed with inflammatory bowel disease (IBD) who are between the ages of 18 and 85 at time of study enrollment.
- The diagnosis of IBD will be based on the standard IBD criteria including biochemical and colonoscopy screening.
- Women with inflammatory bowel disease of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation.
- Patients between the ages of 18 and 85 without history of IBD or colon cancer.
Description
Inclusion Criteria:
- Patients diagnosed with inflammatory bowel disease (IBD) who are between the ages of 18 and 85 at time of study enrollment.
- The diagnosis of IBD will be based on the standard IBD criteria including biochemical and colonoscopy screening.
- Women with inflammatory bowel disease of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation.
- Patients between the ages of 18 and 85 without history of IBD or colon cancer.
Exclusion Criteria:
- Patients with known liver disease.
- Patients unable to provide informed consent.
- Prisoners and institutionalized individuals.
- Patients with a history of colorectal cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Control Group
Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
|
50 ml will be collected
50 ml will be collected
Three 25 ml tubes will be collected
|
|
Inflammatory bowel disease (IBD)
Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
|
50 ml will be collected
50 ml will be collected
Three 25 ml tubes will be collected
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Study Participants
Time Frame: 50 years
|
Total number of participants in the study
|
50 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urine Collection
Time Frame: 50 years
|
Total number of urine samples collected
|
50 years
|
|
Blood Collection
Time Frame: 50 years
|
Total number of blood samples collected
|
50 years
|
|
Stool Collection
Time Frame: 50 years
|
Total number of stool samples collected
|
50 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Konstantinos N. Lazaridis, MD, Mayo Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2018
Primary Completion (Estimated)
December 1, 2065
Study Completion (Estimated)
December 1, 2065
Study Registration Dates
First Submitted
November 27, 2018
First Submitted That Met QC Criteria
November 27, 2018
First Posted (Actual)
November 28, 2018
Study Record Updates
Last Update Posted (Actual)
February 17, 2026
Last Update Submitted That Met QC Criteria
February 12, 2026
Last Verified
February 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Intestinal Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Gastroenteritis
- Colitis
- Colitis, Ulcerative
- Inflammatory Bowel Diseases
- Investigative Techniques
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Blood Specimen Collection
- Urine Specimen Collection
Other Study ID Numbers
- 18-007941
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Cook Children's Health Care SystemNot yet recruitingIBD | IBD - Inflammatory Bowel Disease | IBD (Inflammatory Bowel Disease)United States
-
Ningbo Medical Center Lihuili HospitalRecruitingInflammatory Bowel Disease (IBD)China
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingIBD - Inflammatory Bowel DiseaseItaly
-
Chang Kyun LeeChonnam National University Hospital; Kyungpook National University Hospital; Chung-Ang University Hosptial, Chung-Ang University College of Medicine and other collaboratorsRecruitingInflammatory Bowel Disease (IBD)Korea, Republic of
-
Xijing HospitalNot yet recruitingInflammatory Bowel Diseases (IBD)China
-
Assiut UniversityNot yet recruitingInflammatory Bowel Disease (IBD)
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Texas Southwestern Medical CenterEnrolling by invitationInflammatory Bowel Disease | Inflammatory Bowel Disease (IBD)United States
-
University Hospital, GrenobleInstitute for Advanced Biosciences (IAB), GrenobleNot yet recruitingInflammatory Bowel Disease (IBD)France
Clinical Trials on Blood Draw
-
Abbott Point of CareCompletedPrecision of Potassium (K) Test in Capillary Whole BloodUnited States, Canada
-
University Hospital, Strasbourg, FranceNot yet recruitingKidney Transplantation | Humoral Rejection | Kidney Allograft Biopsy | Microvascular Inflammation
-
Turtle Health, Inc.Completed
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCCompletedMelanomaUnited States
-
Shanghai Changzheng HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; West China... and other collaboratorsRecruiting
-
National Heart Centre SingaporeDuke-NUS Graduate Medical SchoolRecruiting
-
University of BonnRecruitingSARS-CoV 2 | COVIDGermany
-
Joseph M. Still Research Foundation, Inc.RecruitingInflammatory Response | Deep Vein Thrombosis | Multi Organ Failure | Nosocomial InfectionUnited States